Search

Your search keyword '"Allergan PLC -- Product development"' showing total 161 results
Start Over Descriptor "Allergan PLC -- Product development"
161 results on '"Allergan PLC -- Product development"'

1. PRESBYOPIA DRUGS: A DROP IN THE BUCKET?

Author

Rita, Rachel

Subjects
Allergan PLC -- Product development, Presbyopia -- Drug therapy, Ophthalmic solutions -- Licensing, certification and accreditation -- Complications and side effects -- Dosage and administration, Pilocarpine -- Licensing, certification and accreditation -- Complications and side effects -- Dosage and administration, Pharmaceutical industry -- Product development, Health
Abstract

With one med available and others coming soon, patients have more options than ever for near vision correction. Do they offer enough to make a difference in a well-established market? [...]

Published
2023

2. ABSSSI Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials by DelveInsight | Merck & Co. Inc., Endo Pharma, Nabriva Therapeutics, Basilea Pharma, Cipher Pharma, Paratek

Subjects
Merck & Company Inc. -- Product development, Paratek Pharmaceuticals Inc. -- Product development, Allergan PLC -- Product development, Business -- Research, Skin -- Care and treatment -- Health aspects, Infection -- Health aspects, Clinical trials -- Health aspects, Dalbavancin -- Health aspects, Antibiotics -- Product development, Pharmaceutical industry -- Product development, Business, Business, international, Zevtera (Medication) -- Product development -- Health aspects
Abstract

M2 PRESSWIRE-July 3, 2024-: ABSSSI Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials by DelveInsight | Merck & Co. Inc., Endo Pharma, Nabriva Therapeutics, Basilea Pharma, Cipher Pharma, [...]

Published
2024

3. Benign Prostatic Hyperplasia Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Boehringer Ingelheim, Merck & Co. Inc., Allergan PLC

Subjects
Astellas Pharma Inc. -- Product development, Merck & Company Inc. -- Product development, Allergan PLC -- Product development, Boehringer Ingelheim GmbH -- Product development, Nymox Pharmaceutical Corp. -- Product development, Therapeutics Inc. -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Prostate -- Hypertrophy, Drugs -- Product development, Clinical trials -- Reports, Instrument industry -- Product development, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-May 6, 2024-: Benign Prostatic Hyperplasia Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Boehringer Ingelheim, Merck & Co. Inc., Allergan [...]

Published
2024

4. Postoperative Pain Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Novartis AG, Allergan plc, Teva

Subjects
Allergan PLC -- Product development, Novartis AG -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Business -- Research, Clinical trials -- Reports, Pain -- Care and treatment, Analgesics -- Product development, Pain, Postoperative -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-November 9, 2023-: Postoperative Pain Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Novartis AG, Allergan plc, Teva [...]

Published
2023

5. Cystic Fibrosis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Genentech Inc., Novartis AG, Gilead Sciences Inc., Vertex Pharma

Subjects
Allergan PLC -- Product development, Genentech Inc. -- Product development, Vertex Pharmaceuticals Inc. -- Product development, AbbVie Inc. -- Product development, Gilead Sciences Inc. -- Product development, Novartis AG -- Product development, Biological products industry -- Product development, Business -- Research, Medical research -- Reports, Medicine, Experimental -- Reports, Cystic fibrosis -- Reports, Biotechnology industry -- Product development, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 6, 2023-: Cystic Fibrosis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Genentech Inc., Novartis AG, Gilead Sciences Inc., Vertex [...]

Published
2023

6. Global Energy-based Aesthetic Devices Market valued at $5 billion in 2021, is projected to witness a lucrative growth rate of 10% in the coming 5 years

Subjects
Allergan PLC -- Product development, Business -- Research, Product development -- Statistics, Pharmaceutical industry -- Statistics -- Product development, Time to market, Banking, finance and accounting industries, Business
Abstract

BRUSSELS, BELGIUM, Nov. 16, 2022 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=6V06CDqxYmBrrb8PlGaNaDPwbFW2y6tn9sdr5kuXtf94VGEre4iBG56ncs7bkKzT1v6hS2c7O-nXHO5jHvjRiORIT2wCV6T_NX3buD2tKMF-Fwb4QCXjdh-tIuR3p-zMhGiQT2HWl9jQ2yExmW8vxig5uYHcWa5vB1gqex7JL58= are used for a variety of skin procedures, including body sculpting, skin tightening, and resurfacing. These devices are precise, targeted medical [...]

Published
2022

7. US FDA approves Allergan's NDA for Durysta for ocular hypertension patients

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Hypertension, Patient compliance, Pharmaceutical industry -- Product development, Bimatoprost -- Product development, Open-angle glaucoma, Industrial research, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc, a leading global pharmaceutical company announced that the US Food and Drug Administration (US FDA) has approved the company's New Drug Application (NDA) for Durysta (bimatoprost implant) 10 [...]

Published
2020

8. Allergan, Editas Medicine begin patient dosing in phase 1/2 trial of CRISPR Medicine AGN-151587 (EDIT-101) to treat LCA1

Subjects
Allergan PLC -- Product development, Clinical trials, Medical research, Pharmaceutical industry -- Product development, Blindness -- Care and treatment, Genetic disorders -- Care and treatment, Genomics, Genetic research, Genes, Health, Pharmaceuticals and cosmetics industries, Oregon Health & Science University
Abstract

Allergan plc, a leading global pharmaceutical company, and Editas Medicine, Inc., a leading genome editing company, announced the treatment of the first patient in the BRILLIANCE clinical trial of AGN-151587 [...]

Published
2020

9. Study Results from Allergan Plc Update Understanding of Biotechnology (Bimatoprost Implant Biodegradation In the Phase 3, Randomized, 20-month Artemis Studies)

Subjects
Allergan PLC -- Product development, Bimatoprost -- Product development, Biotechnology, Biotechnology industry -- Product development, Clinical trials, Biodegradation, Pharmaceutical industry -- Product development, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2022 DEC 14 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Biotechnology have been published. According to news reporting out of Irvine, [...]

Published
2022

10. Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY(TM) (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia)

Subjects
Allergan PLC -- Product development, Presbyopia, Ophthalmic drugs -- Product development, Adults, Business, News, opinion and commentary, Vuity (Medication) -- Product development
Abstract

VUITY is the first and only eye drop to treat presbyopia, or age-related blurry near vision, in adults and is FDA-approved for once-daily administration In the VIRGO trial evaluating twice-daily [...]

Published
2022

11. Allergan announces positive phase 3 ACHIEVE I trial results for ubrogepant

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Drug therapy, Periodicals, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc announced that positive results from ACHIEVE I (UBR-MD-01), a robust phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the December [...]

Published
2019

12. Allergan, Molecular Partners present data from phase 3 studies of Abicipar in patients with neovascular wet AMD at AAO m

Subjects
Allergan PLC -- Product development, Clinical trials, Macular degeneration, Ranibizumab, Medical research, Pharmaceutical industry -- Product development, Ophthalmology, Pharmaceuticals and cosmetics industries, American Academy of Ophthalmology
Abstract

Allergan plc, a leading global pharmaceutical company, and Molecular Partners, a clinical-stage biopharmaceutical company, announced two-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with [...]

Published
2019

13. US FDA accepts Allergan's NDA for Bimatoprost SR for patients with open-angle glaucoma/ocular hypertension

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Hypertension -- Care and treatment, Patient compliance, Pharmaceutical industry -- Product development, Bimatoprost -- Product development, Glaucoma -- Care and treatment, Open-angle glaucoma, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc, a leading global pharmaceutical company with more than 70 years of heritage in eye care, announced that the US FDA has accepted the company's New Drug Application (NDA) [...]

Published
2019

14. Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D

Subjects
Allergan PLC -- Product development, Clinical trials, Physical fitness, Irritable bowel syndrome, Gastrointestinal diseases, Pharmaceutical industry -- Product development, Pain management, Linaclotide, Diarrhea, Obesity, Editors, Health
Abstract

2019 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, announced the initiation of [...]

Published
2019

15. Allergan, Ironwood say LINZESS trial met primary multi-component endpoint

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Clinical trials, Work experience, Business, News, opinion and commentary, Linzess (Medication)
Abstract

Ironwood Pharmaceuticals, Inc. (IRWD) and Allergan plc (AGN) announced positive topline data from a Phase IIIb clinical trial evaluating LINZESS 290 mcg on multiple abdominal symptoms in adult patients with [...]

Published
2019

16. US FDA accepts Allergan's NDA for ubrogepant for acute treatment of migraine

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Medical research, Migraine -- Drug therapy, Prescriptions (Drugs) -- Product development, Legal fees, Clinical trials, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for ubrogepant for the acute treatment of migraine in adults. The [...]

Published
2019

17. AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI) in Psoriatic Arthritis at ACR Convergence 2021

Subjects
Allergan PLC -- Product development, AbbVie Inc. -- Product development, Psoriatic arthritis -- Drug therapy, Antiarthritic agents -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

- The 24-week integrated results from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluated the efficacy and safety of risankizumab (SKYRIZI) versus placebo for the treatment of [...]

Published
2021

18. New Therapeutics Expand Intervention Options: The innovations include a refutable implant that treats AMD with far fewer injections, an eye drop for presbyopia that constricts pupils and a nasal spray that boosts tear production

Subjects
Allergan PLC -- Product development, Genentech Inc. -- Product development, Presbyopia -- Drug therapy, Prosthesis -- Licensing, certification and accreditation, Biotechnology industry -- Product development, Implants, Artificial -- Licensing, certification and accreditation, Ophthalmic drugs -- Licensing, certification and accreditation, Macular degeneration -- Care and treatment, Intranasal medication -- Licensing, certification and accreditation, Pharmaceutical industry -- Product development, Health
Abstract

No fewer than four new ophthalmic drugs received FDA approval in October, and each hopes to distinguish itself with a unique approach to care. Retina specialists will have access to [...]

Published
2021

19. Allergan reports positive 3 month topline results from second phase 3 study of Bimatoprost SR

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc, a leading global pharmaceutical company, announced positive 3-month topline results from the second pivotal clinical trial of Bimatoprost SR, a first-in-class sustained-release, biodegradable implant for the reduction of [...]

Published
2019

20. Overactive Bladder Pipeline Shows Rapid Advancements in the Clinical Trials: A Review by DelveInsight

Subjects
Allergan PLC -- Product development, Bayer AG -- Product development, Medical research, Medicine, Experimental, Trospium -- Product development, Clinical trials, Darifenacin -- Product development, Pharmaceutical industry -- Product development, Business, international, Law
Abstract

(GlobeNewswire) - Overactive Bladder Pipeline Shows Rapid Advancements in the Clinical Trials: A Review by DelveInsight Overactive Bladder therapies with different mechanisms of action are currently being studied with excellent [...]

Published
2021

21. Overactive Bladder Pipeline Shows Rapid Advancements in the Clinical Trials: A Review by DelveInsight

Subjects
Allergan PLC -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Trospium -- Product development, Clinical trials -- Reports, Darifenacin -- Product development, Pharmaceutical industry -- Product development, Banking, finance and accounting industries, Business
Abstract

Los Angeles, USA, Jun 07, 2021 (GLOBE NEWSWIRE via COMTEX) -- Overactive Bladder Pipeline Shows Rapid Advancements in the Clinical Trials: A Review by DelveInsight Overactive Bladder therapies with different [...]

Published
2021

22. Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI) Achieved Endoscopic Response and Clinical Remission at One Year

Subjects
Allergan PLC -- Product development, AbbVie Inc. -- Product development, Interleukins -- Product development, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

- In Crohn's disease patients with clinical response to risankizumab IV induction treatment, a significantly greater proportion of patients treated with risankizumab 360 mg SC achieved endoscopic response and clinical [...]

Published
2021

23. The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ (upadacitinib) in Atopic Dermatitis

Subjects
Allergan PLC -- Product development, AbbVie Inc. -- Product development, Atopic dermatitis -- Care and treatment, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Rinvoq (Medication) -- Product development
Abstract

NORTH CHICAGO, Ill., May 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced The Lancet published primary analysis results from the pivotal global Phase 3 clinical trials -- Measure Up [...]

Published
2021

24. New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ(TM) (upadacitinib) in Psoriatic Arthritis

Subjects
Allergan PLC -- Product development, AbbVie Inc. -- Product development, Rheumatoid factor, Arthritis, Adalimumab -- Product development, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Rinvoq (Medication) -- Product development, Humira (Medication) -- Product development
Abstract

- In SELECT-PsA 1, RINVOQ(TM) (upadacitinib, 15 mg and 30 mg) improved key joint and skin symptoms up to 24 weeks, including enthesitis[1] - Both doses of upadacitinib significantly improved [...]

Published
2021

25. Risankizumab (SKYRIZI) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients

Subjects
Allergan PLC -- Product development, AbbVie Inc. -- Product development, Psoriatic arthritis -- Care and treatment, Adalimumab -- Product development, Skin, Interleukins -- Product development, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

- In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved the primary endpoint of ACR20 response at week 24, respectively, versus 34 and 27 percent receiving [...]

Published
2021

26. Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results for Investigational AGN-190584 for the Treatment of Presbyopia

Subjects
Allergan PLC -- Product development, Presbyopia -- Care and treatment, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

- Presbyopia is a common, progressive condition that reduces the aging eye's ability to focus on near objects and affects nearly four out of 10 people in the U.S. - [...]

Published
2020

27. New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients

Subjects
Allergan PLC -- Product development, Roche Holding AG -- Product development, Medical research, Medicine, Experimental, Biotechnology industry -- Product development, Clinical trials, Chemotherapy, Cancer -- Chemotherapy, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Venclexta (Medication) -- Product development
Abstract

- Data from Phase 3 VIALE-A study showed venetoclax plus azacitidine reduced the risk of death by 34% compared to azacitidine plus placebo in newly-diagnosed patients with AML who are [...]

Published
2020

28. Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1|2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Blindness, Genes, Genetic disorders, Genomics, Health, General interest, News, opinion and commentary, Oregon Health & Science University
Abstract

DUBLIN: Editas Medicine, Inc. has issued the following press release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, [...]

Published
2020

29. Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Genomics, Banking, finance and accounting industries, Business, Oregon Health & Science University
Abstract

DUBLIN, Ireland and CAMBRIDGE, Mar 04, 2020 (GLOBE NEWSWIRE via COMTEX) -- AGN-151587 (EDIT-101) is the first in vivo CRISPR medicine to be administered to patients Additional patient enrollment to [...]

Published
2020

30. US FDA accepts NDA to review Seysara for treatment of moderate to severe acne

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Antiacne agents, Acne -- Care and treatment, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Seysara (Medication) -- Product development
Abstract

Allergan plc, a leading global pharmaceutical company, and Paratek Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of therapies based upon tetracycline chemistry, announced that the US Food [...]

Published
2017

31. US FDA accepts Allergan's sNDA filing for Avycaz

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Communicable diseases -- Care and treatment, Pneumonia -- Care and treatment, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Avycaz (Medication)
Abstract

Allergan plc, a leading global pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Avycaz (ceftazidime and avibactam) for [...]

Published
2017

32. Allergan announces new data from CENTAUR phase 2b study supports continued development of CVC in ongoing phase 3 AURORA trial

Subjects
Allergan PLC -- Product development, Clinical trials, Liver diseases -- Care and treatment, Medical research, Pharmaceutical industry -- Product development, Liver, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc announced top-line results from new data for the CENTAUR phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis [...]

Published
2017

33. Allergan receives refusal to file letter from FDA for Vraylar

Subjects
Allergan PLC -- Product development, Antipsychotic agents -- Licensing, certification and accreditation, Schizophrenia -- Care and treatment, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

Allergan announced that it received a refusal to file, or RTF letter from the FDA regarding its supplemental new drug application, or sDNA, for Vraylar for treatment of negative symptoms [...]

Published
2017

34. Allergan says new CENTAUR study data supports continued Cenicriviroc development

Subjects
Allergan PLC -- Product development, Anti-HIV agents -- Testing, HIV infections -- Drug therapy, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, CENTAUR (Medication) -- Testing
Abstract

Allergan announced top-line results from new data for the CENTAUR Phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc, or CVC, for the treatment of liver fibrosis [...]

Published
2017

35. Allergan's sNDA for avycaz gets US FDA nod to include new phase III data in patients with cUTI, including pyelonephritis

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Pyelonephritis -- Care and treatment, Urinary tract infections -- Care and treatment, Pharmaceutical industry -- Product development, Drug approval, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc, a leading global pharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) to update the label for [...]

Published
2017

36. Studies from Justus-Liebig-University Have Provided New Data on Clinical Trials and Studies (Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 ...)

Subjects
Allergan Inc. (Irvine, California) -- Product development, Allergan PLC -- Product development, AstraZeneca PLC -- Product development, Clinical trials -- Health aspects, Pyelonephritis -- Research -- Health aspects, Physical fitness -- Health aspects, Urinary tract infections -- Research -- Health aspects, Medical research -- Health aspects, Pharmaceutical industry -- Product development -- Health aspects, Ceftazidime -- Research -- Product development -- Health aspects, Health
Abstract

2017 JAN 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Clinical Research - Clinical Trials and Studies. [...]

Published
2017

37. Alzheimer's Disease Global Clinical Trials Review, H2, 2019 - Pfizer Inc, Eisai Co Ltd, Allergan Plc & The Lundbeck Foundation

Subjects
Allergan PLC -- Product development, Pfizer Inc. -- Product development, Eisai Company Ltd. -- Product development, Clinical trials, Anti-Alzheimer's disease agents -- Product development, Pharmaceutical industry -- Product development, Alzheimer's disease, Diseases, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Alzheimer's Disease Global Clinical Trials Review, H2, 2019' clinical trials has been added to ResearchAndMarkets.com's offering. Summary The clinical [...]

Published
2020

38. Global Wrinkles Clinical Trials Review, H2 2019 - Allergan Plc, Bausch Health Companies Inc, L'Oreal SA & Huons Global Co Ltd

Subjects
Allergan PLC -- Product development, L'Oreal S.A. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Cosmetics industry -- Product development, Diseases, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Wrinkles Global Clinical Trials Review, H2, 2019' clinical trials has been added to ResearchAndMarkets.com's offering. Wrinkles Global Clinical Trials [...]

Published
2020

39. Alzheimer's Disease Global Clinical Trials Review, H2, 2019 - Pfizer Inc, Eisai Co Ltd, Allergan Plc & The Lundbeck Foundation - ResearchAndMarkets.com

Subjects
Allergan PLC -- Product development, Pfizer Inc. -- Product development, Eisai Company Ltd. -- Product development, Clinical trials, Anti-Alzheimer's disease agents -- Product development, Pharmaceutical industry -- Product development, Alzheimer's disease, Diseases, Business, Business, international
Abstract

DUBLIN -- The 'Alzheimer's Disease Global Clinical Trials Review, H2, 2019' clinical trials has been added to ResearchAndMarkets.com's offering. Summary The clinical trial report, Alzheimer's Disease Global Clinical Trials Review, [...]

Published
2020

40. Global Wrinkles Clinical Trials Review, H2 2019 - Allergan Plc, Bausch Health Companies Inc, L'Oreal SA & Huons Global Co Ltd - ResearchAndMarkets.com

Subjects
Allergan PLC -- Product development, L'Oreal S.A. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Cosmetics industry -- Product development, Diseases, Business, Business, international
Abstract

DUBLIN -- The 'Wrinkles Global Clinical Trials Review, H2, 2019' clinical trials has been added to ResearchAndMarkets.com's offering. Wrinkles Global Clinical Trials Review, H2, 2019 Summary The clinical trial report, [...]

Published
2020

41. Global Wrinkles Clinical Trials Review, H2 2019 - Allergan Plc, Bausch Health Companies Inc, L' Oreal SA & Huons Global Co Ltd

Subjects
Allergan PLC -- Product development, L'Oreal S.A. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Cosmetics industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-January 28, 2020-: Global Wrinkles Clinical Trials Review, H2 2019 - Allergan Plc, Bausch Health Companies Inc, L' Oreal SA & Huons Global Co Ltd (C)1994-2020 M2 COMMUNICATIONS RDATE:28012020 [...]

Published
2020

42. Alzheimer's Disease Global Clinical Trials Review, H2, 2019 - Pfizer Inc, Eisai Co Ltd, Allergan Plc & The Lundbeck Foundation

Subjects
Allergan PLC -- Product development, Pfizer Inc. -- Product development, Eisai Company Ltd. -- Product development, Clinical trials, Anti-Alzheimer's disease agents -- Product development, Pharmaceutical industry -- Product development, Alzheimer's disease, Business, Business, international
Abstract

M2 PRESSWIRE-January 27, 2020-: Alzheimer's Disease Global Clinical Trials Review, H2, 2019 - Pfizer Inc, Eisai Co Ltd, Allergan Plc & The Lundbeck Foundation (C)1994-2020 M2 COMMUNICATIONS RDATE:27012020 The 'Alzheimer's [...]

Published
2020

43. Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Care and treatment, Periodicals, General interest, News, opinion and commentary
Abstract

DUBLIN: Allergan plc has issued the following press release: Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the [...]

Published
2019

44. Ireland : Allergan Announces Positive Phase 3 Achieve I Trial Results For Ubrogepant Published In The New England Journal Of Medicine

Subjects
Allergan PLC -- Product development, Migraine -- Drug therapy, Clinical trials, Pharmaceutical industry -- Product development, Business, international, Ubrelvy (Medication) -- Product development
Abstract

Allergan plc announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the December [...]

Published
2019

45. Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine

Subjects
Allergan PLC -- Product development, Migraine -- Care and treatment, Clinical trials, Pain -- Care and treatment, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Ubrelvy (Medication) -- Product development
Abstract

-- Published data from a second robust Phase 3 clinical trial demonstrated efficacy, safety and tolerability of ubrogepant, an orally-administered CGRP receptor antagonist (gepant) -- -- Compared to placebo, ubrogepant [...]

Published
2019

46. Ireland : Allergan Announces Positive Phase 3 Achieve Ii Trial Results For Ubrogepant Published In The Journal Of The American Medical Association

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Drug therapy, Business, international
Abstract

Allergan plc announced that positive results from ACHIEVE II (UBR-MD-02), a pivotal Phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the November [...]

Published
2019

47. Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in The Journal of the American Medical Association

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Care and treatment, General interest, News, opinion and commentary
Abstract

DUBLIN: Allergan plc has issued the following press release: Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE II (UBR-MD-02), a pivotal Phase 3 clinical trial evaluating the [...]

Published
2019

48. Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in The Journal of the American Medical Association

Subjects
Allergan PLC -- Product development, Migraine -- Care and treatment, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

-- Pivotal Phase 3 clinical trial reinforced efficacy, safety and tolerability of ubrogepant, an orally-administered CGRP receptor antagonist (gepant) -- -- Acute treatment of migraine with ubrogepant compared with placebo [...]

Published
2019

49. Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Subjects
Allergan PLC -- Product development, Clinical trials -- Physiological aspects, Macular degeneration -- Physiological aspects, Ranibizumab -- Physiological aspects, Medical research -- Physiological aspects, Pharmaceutical industry -- Product development -- Physiological aspects, Ophthalmology, General interest, News, opinion and commentary
Abstract

DUBLIN: Allergan plc has issued the following press release: Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (SIX: [...]

Published
2019

50. Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Subjects
Allergan PLC -- Product development, Macular degeneration -- Physiological aspects, Pharmaceutical industry -- Product development -- Physiological aspects, Business, News, opinion and commentary
Abstract

- Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year - - [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results